Wall Street analysts predict that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will announce $1.21 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Enanta Pharmaceuticals’ earnings. The highest EPS estimate is $1.31 and the lowest is $1.16. Enanta Pharmaceuticals posted earnings of $1.86 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 34.9%. The firm is scheduled to issue its next earnings report on Monday, November 19th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of $3.37 per share for the current year, with EPS estimates ranging from $3.32 to $3.39. For the next financial year, analysts forecast that the company will post earnings of $2.73 per share, with EPS estimates ranging from $1.17 to $4.13. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.97 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.98 by ($0.01). The company had revenue of $57.26 million during the quarter, compared to analysts’ expectations of $56.59 million. Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%.

Several analysts recently issued reports on the company. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research note on Thursday, August 9th. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 22nd. UBS Group cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 8th. Oppenheimer assumed coverage on Enanta Pharmaceuticals in a research report on Thursday, May 24th. They set a “buy” rating and a $135.00 price objective on the stock. Finally, Roth Capital assumed coverage on Enanta Pharmaceuticals in a research report on Wednesday, June 6th. They set a “buy” rating and a $133.00 price objective on the stock. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Enanta Pharmaceuticals has an average rating of “Hold” and a consensus target price of $107.60.

In other news, insider Jay R. Luly sold 35,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, July 6th. The shares were sold at an average price of $125.24, for a total transaction of $4,383,400.00. Following the completion of the transaction, the insider now directly owns 625,049 shares in the company, valued at $78,281,136.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $92.32, for a total transaction of $383,589.60. Following the transaction, the vice president now owns 4,465 shares of the company’s stock, valued at $412,208.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,200 shares of company stock worth $5,396,807. Insiders own 10.56% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Meadow Creek Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $110,000. SG Americas Securities LLC purchased a new position in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $112,000. Riverhead Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $129,000. Glen Harbor Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $140,000. Finally, Zeke Capital Advisors LLC purchased a new position in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $216,000. Hedge funds and other institutional investors own 77.62% of the company’s stock.

ENTA opened at $90.58 on Friday. The stock has a market capitalization of $1.73 billion, a PE ratio of 99.54 and a beta of 0.87. Enanta Pharmaceuticals has a 12 month low of $42.49 and a 12 month high of $127.77.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Further Reading: Hedge Funds Explained

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.